Mikhail Blagosklonny

Last updated
Mikhail Blagosklonny
DiedOctober 2024
Alma mater First Pavlov State Medical University of St. Peterburg
Scientific career
Fields Anti-aging medicine, oncology
Institutions

Mikhail Blagosklonny was a scientist who studied cancer and aging. He died in October 2024. He was an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York. [1]

Contents

Career

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[ citation needed ] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center. [2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs. [3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them. [1]

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension. [4] He advocates for rapamycin use in longevity research. [5]

Editorial activities

Blagosklonny is editor-in-chief of Aging, [6] Cell Cycle, [7] and Oncotarget . [8] In addition, he is associate editor of Cancer Biology & Therapy [9] and a member of the editorial board of Cell Death & Differentiation . [10]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall, [11] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" [12] in July 2015. [11] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact. [13]

Health

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. [14] He died in October 2024 at the age of 63. [15]

References

  1. 1 2 "About Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center . Retrieved May 14, 2021.
  2. ↑ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8 (9): 753–752, May 2009, doi: 10.4161/cbt.8.9.8899
  3. ↑ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8 (9): 753–752. May 2009. doi: 10.4161/cbt.8.9.8899 .
  4. ↑ Stipp, David (2011). "A New Path to Longevity". Scientific American . 306 (1): 32–39. Bibcode:2011SciAm.306f..32S. doi:10.1038/scientificamerican0112-32. PMID   22279832.
  5. ↑ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Bloomberg.com. 12 February 2015. Retrieved November 20, 2016.
  6. ↑ "Editorial Board". Aging. Archived from the original on 2009-01-25. Retrieved 2016-11-20.
  7. ↑ "Editorial Board". Cell Cycle. Taylor & Francis . Retrieved 2016-11-20.
  8. ↑ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  9. ↑ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  10. ↑ "About the journal". Cell Death & Differentiation . Retrieved 2016-11-20.
  11. 1 2 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  12. ↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  13. ↑ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.
  14. ↑ "My battle with cancer". 26 October 2023.
  15. ↑ "Passing of Dr. Misha Blagoskonny". Rapamycin News. Retrieved 2024-10-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.